Entrepreneurial Growth | Oncolytic Virus - 2021 World Medical Innovation Forum
May 2–4, 2022

Entrepreneurial Growth | Oncolytic Virus

Entrepreneurial Growth | Oncolytic Virus

Wednesday, May 19, 2021

2:20 PM – 2:45 PM

In 2020 there were a total of 60 phase I trials for Oncolytic Viruses. There are now dozens of companies pursuing some aspect of OV technology. This panel will address:

  •  How are small companies equipped to address the challenges of developing OV therapies better than large pharma or biotech?
  • Will the success of COVID vaccines based on Adenovirus help the regulatory environment for small companies developing OV products in Europe and the USA?
  • Is there a place for non-viral delivery and other immunotherapy companies to engage in the OV space?  Would they bring any real advantages?
Reid Huber, PhD
  • Partner, Third Rock Ventures
Caroline Breitbach, PhD
  • VP, R&D Programs and Strategy, Turnstone Biologics
Brett Ewald, PhD
  • SVP, Development & Corporate Strategy, DNAtrix
Paul Hallenbeck, PhD
  • President and Chief Scientific Officer, Seneca Therapeutics
Stephen Russell, MD, PhD
  • CEO, Vyriad
  • Q&A

    02:50 PM – 03:05 PM

the Future of Medicine and AI

May 11–13, 2020 | Boston, MA